ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0355

Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial

Georg Schett1, Matthew J. Loza2, Arumugam Palanichamy2, Oliver FitzGerald3, Christopher Ritchlin4, Frédéric Baribaud5 and Kristen Sweet5, 1Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 2Janssen Research & Development, LLC, Spring House, 3Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 4Department of Medicine, University of Rochester Medical Center, Rochester, NY, 5Janssen Research & Development, LLC, Spring House, PA

Meeting: ACR Convergence 2020

Keywords: Biologicals, Biomarkers, clinical trial, Collagen, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Guselkumab (GUS), an interleukin-23p19-subunit monoclonal antibody, demonstrated efficacy compared to placebo (PBO) in reducing skin and musculoskeletal signs and symptoms in patients with active psoriatic arthritis (PsA) in two phase-3 studies, DISCOVER 1 & 2, and in retarding structural damage in DISCOVER 2.1,2 Here we evaluate tissue-derived extracellular matrix (ECM) products3,4 in serum of PsA patients in the DISCOVER 2 study and their relationship with radiographic damage, clinical response, and impact of treatment.

Methods: In DISCOVER 2, patients were treated with GUS 100 mg at Week (w) 0, 4, then every 8w (q8w); GUS 100mg every 4w (q4w); or matching PBO. At w24, PBO subjects were crossed-over to GUS q4w. 11 serum biomarkers of ECM collagen formation (PRO-C1, PRO-C2, PRO-C3, PRO-C4, PRO-C6) and degradation (C1M, C2M, C3M, C4M, C6M, and COL10) were measured (by Nordic Bioscience) in a subset of 260 patients from the DISCOVER 2 program at Weeks 0, 4, 24, & 52 and in 76 healthy controls matched for age, sex, and ethnicity. PsA patients were selected randomly, though enriching for subjects with greatest radiographic changes, at Weeks 24 and 52. Significance defined by P< 0.05 and |fold difference| ≥ 1.25.

Results: At baseline, collagen degradation markers C1M, C3M, C4M, C6M and collagen formation markers PRO-C3 and PRO-C6 were significantly higher in PsA patients compared to matched healthy controls (Figure 1). Baseline C3M, C4M, and C6M were positively correlated to baseline skin and joint disease; baseline C1M, C3M, C4M, C6M, and PRO-C1 were positively correlated to baseline radiographic damage (data not shown). Levels of C1M (a maker indicating breakdown of collagen type I, the major collagen subtype in the bone) were significantly decreased after 24w treatment with GUS (Figure 2), reaching significant differences from placebo with the GUS 100 mg q4w group. For the PBO patients who crossed over to GUS at w24, there was also a reduction in this marker observed at w52 (Figure 2). In patients treated with GUS or PBO, there were not significant differences in baseline expression levels of the analytes in responders (patients achieving ACR20 at w24) compared with non-responders. However, ACR20 responders in the combined GUS group had a significantly greater reduction in C1M levels compared to non-responders (Figure 3).

Conclusion: This work provides evidence that collagen biomarkers in serum are dysregulated in patients with PsA compared to healthy controls, and that GUS impacts levels of these proteins. Importantly, C1M serves as a biomarker that tracks with joint response. We observed a greater reduction in C1M in ACR responders compared to non-responders, providing insight into how GUS may be working to protect from degradation of bone in PsA.

References:

  1. Deodhar A et al. Lancet. 2020;395:1115
  2. Mease P et al. Lancet. 2020;395:1126
  3. Gudmann N. S. et al. Clin. Exp. Rheumatol. 2017;35: 653–659
  4. Sardar S et al. Annals of the Rheum Dis 2019;78 (Suppl 2): https://ard.bmj.com/content/78/Suppl_2/867.1


Disclosure: G. Schett, None; M. Loza, Janssen Research & Development, LLC, 1, 3; A. Palanichamy, Janssen Research & Development, LLC, 1, 3; O. FitzGerald, AbbVie Inc., 2, 5, Amgen, 2, 5, Bristol Myers Squibb, 2, 5, Celgene, 2, 5, Janssen, 2, 5, Eli Llilly, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, UCB, 2, 5; C. Ritchlin, None; F. Baribaud, Janssen Research & Development, LLC, 1, 3; K. Sweet, Janssen Research & Development, LLC, 3.

To cite this abstract in AMA style:

Schett G, Loza M, Palanichamy A, FitzGerald O, Ritchlin C, Baribaud F, Sweet K. Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/collagen-turnover-markers-are-associated-with-active-psoriatic-arthritis-and-decrease-with-guselkumab-treatment-in-a-phase-3-clinical-trial/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/collagen-turnover-markers-are-associated-with-active-psoriatic-arthritis-and-decrease-with-guselkumab-treatment-in-a-phase-3-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.